TopMedTalk Journal Review of FEDORA study

The BJA recently published the FEDORA RCT of 420 patients. The study’s statistically significant results reinforce the UK’s NICE recommendation to use oesophageal Doppler monitor (ODM).

Now, TopMedTalk, disseminator of medical news, has reviewed the paper in its Journal Club, hosted by Professor Monty Mythen of UCL, London.

You can listen to the review here, or enjoy some highlights, as follows:

A multicentre, randomised controlled study, FEDORA concluded that:

  • Haemodynamic Optimisation significantly reduced post-op complications and length of stay in low to moderate risk patients undergoing major abdominal surgery
  • Goal-Directed Haemodynamic Therapy is beneficial even in low to moderate risk patients.

Prof Mythen points out that the Cochrane collaboration has identified 70 prospective, randomised controlled trials on this subject. Moreover, every time meta-analysis has been performed, the result is broadly the same.

Deltex Managing Director Andy Mears states; “FEDORA is a landmark study: It is the first RCT showing outcome benefit in patients having low to moderate abdominal surgery using a GDHT protocol that is only achievable using the ODM. We’re grateful to the clinicians involved for delivering such a complete study, and to Prof Mythen for such a comprehensive review on TopMedTalk.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Deltex Medical Group Plc

    More articles like this

    Deltex Medical Group Plc

    Deltex Medical Group plc in a strong financial position

    Nigel Keen, Chairman of Deltex Medical, commented: “The successful £2,050,000 fund raising in February 2018 has put the Group in a stronger financial position – allowing us to improve our business structure. “We made a number

    Deltex Medical Group Plc

    INTERVIEW: Deltex Medical Group New CEO Andy Mears

    Deltex Medical Group Plc (LON:DEMG) New CEO Andy Mears talks to DirectorsTalk about his new position. Andy talks about his background, how he thinks Deltex is positioned, his plans for the next 12 months and the

    Deltex Medical Group Plc

    Deltex Medical Group plc New Chief Executive

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring, announced today that Ewan Phillips has resigned as Chief Executive and as a Director of the Company with immediate effect. Mr. Phillips recently approached Deltex’s

    Deltex Medical Group Plc

    Another Successful Learning Event Sponsored by Deltex

    May 28th saw Deltex Medical Group supporting Current Initiatives, Research and the Role of Haemodynamic Monitoring at London’s Montague Hotel. Held under the auspices of the EBPOM organisation (Evidence Based PeriOperative Medicine), the congress saw keynote presentations from

    Deltex Medical Group Plc

    CEO Q&A with Ewan Phillips at Deltex Medical Group plc (LON:DEMG)

    Deltex Medical Group’s Ewan Phillips discusses their full year results, what’s been happening operationally, their strategy for the next 12 months and what investors should look forward to in the near future in this exclusive interview with DirectorsTalk

    Deltex Medical Group Plc

    Deltex Medical Group PLC Investor Event

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), today announced that it will be hosting an investor event on 22 May 2018 following the publication of its full year results for

    Deltex Medical Group Plc

    Deltex Sponsoring Evidence-Based Clinical Event

    Deltex Medical will be supporting a forthcoming congress in London on May 28th. Current Initiatives, Research and the Role of Hemodynamic Monitoring is free to attend for clinicians and healthcare providers who are interested in the principles and

    Deltex Medical Group Plc

    Critical caring

    It takes a plethora of products and people to provide patients premium protection. Changing payment models, the digitization of healthcare and the need to deliver higher quality care at a lower cost are driving significant change